trial

N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis

NCTId NCT01354132
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 20 (actual)
Sponsored by Beth Israel Deaconess Medical Center
Primary completion 2014-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
20 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2011-05
Primary completion
2014-08
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
N-acetylcysteine

Sponsors

Beth Israel Deaconess Medical CenterLead Sponsor
Center de Neurosciences Psychiatrique, Lausanne, SwitzerlandCollaborator

Investigators

2
Ann Cousins, PhD, APRNStudy Director
T. U. Wilson Woo, MD, PhDStudy Chair

Sites

2 total
Boston, United StatesBoston, United States

Linked catalysts

1
N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis — primary completion2014-08

Facts & assertions

4 sourced
Enrollment
20
Phase
PHASE2
Primary Completion Date
2014-08
Status
COMPLETED
relationships
The graph out of here
drug
N-acetylcysteine
drug
lead_sponsor
Beth Israel Deaconess Medical Center
company
collaborator
Center de Neurosciences Psychiatrique, Lausanne, Switzerland
company
indication
Schizophrenia
indication
Schizophrenic Psychoses
indication
investigator
Ann Cousins, PhD, APRN
person
T. U. Wilson Woo, MD, PhD
person